CSCO Guidelines Conference | Academician Jinming Yu: From the “Jinan Miracle” in Radiation Therapy to Advancing Immunotherapy and International Collaboration

CSCO Guidelines Conference | Academician Jinming Yu: From the “Jinan Miracle” in Radiation Therapy to Advancing Immunotherapy and International Collaboration

2025.04.29
The 2025 CSCO Guidelines Conference, co-hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, was successfully held in Jinan, April 18–19, 2025. Leading experts from across the country gathered once again to exchange cutting-edge research, discuss clinical hot topics, and witness the release of updated CSCO guidelines. Oncology Frontier had the honor of interviewing the conference chair, CSCO Council President, and Academician Jinming Yu of Shandong Cancer Hospital, who shared insights into proton therapy, combined radiotherapy and immunotherapy, and CSCO’s path toward deeper international collaboration.
Writing China’s Own Guidelines: Professor Zefei Jiang on the Evolution and Global Vision of the CSCO Breast Cancer Guidelines

Writing China’s Own Guidelines: Professor Zefei Jiang on the Evolution and Global Vision of the CSCO Breast Cancer Guidelines

2025.04.23
As one of the five initial professional guideline projects launched by the Chinese Society of Clinical Oncology (CSCO) in 2016, the CSCO Breast Cancer Guidelines (CSCO BC Guidelines) have become a cornerstone of breast cancer care in China. Since the publication of the first edition in 2017, the guidelines have undergone yearly updates, evolving in both content and format. Today, they are available in multiple versions—including Chinese and English editions, pocket guides, patient education materials, and AI-based platforms—earning broad recognition from Chinese clinicians and international oncology peers alike.
Professor Zhengqiang Yang Offers In-Depth Interpretation of the 2024 Edition of the Primary Liver Cancer Guidelines: Updates in Interventional and Local Therapies

Professor Zhengqiang Yang Offers In-Depth Interpretation of the 2024 Edition of the Primary Liver Cancer Guidelines: Updates in Interventional and Local Therapies

2025.04.23
Since the release of the 2022 edition of the Primary Liver Cancer Diagnosis and Treatment Guidelines, numerous high-quality studies—both domestic and international—have advanced the field of hepatocellular carcinoma (HCC), especially in diagnosis, staging, and treatment. Research reflecting China's real-world clinical settings has provided important theoretical guidance for the management of liver cancer. Building on accumulated clinical experience, the National Health Commission has organized expert teams to revise the guidelines, culminating in the publication of the 2024 edition, which introduces comprehensive updates across screening, diagnosis, and treatment.